September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Factors associated with retreatment after photodynamic therapy combined with intravitreal ranibizumab for polypoidal choroidal vasculopathy
Author Affiliations & Notes
  • Wataru Kikushima
    Ophthalmology, University of Yamanashi, Chuo, Yamanashi, Japan
  • Yoichi Sakurada
    Ophthalmology, University of Yamanashi, Chuo, Yamanashi, Japan
  • Atsushi Sugiyama
    Ophthalmology, University of Yamanashi, Chuo, Yamanashi, Japan
  • Naohiko Tanabe
    Ophthalmology, University of Yamanashi, Chuo, Yamanashi, Japan
  • Seigo Yoneyama
    Ophthalmology, University of Yamanashi, Chuo, Yamanashi, Japan
  • Hiroyuki Iijima
    Ophthalmology, University of Yamanashi, Chuo, Yamanashi, Japan
  • Footnotes
    Commercial Relationships   Wataru Kikushima, None; Yoichi Sakurada, None; Atsushi Sugiyama, None; Naohiko Tanabe, None; Seigo Yoneyama, None; Hiroyuki Iijima, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 3332. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Wataru Kikushima, Yoichi Sakurada, Atsushi Sugiyama, Naohiko Tanabe, Seigo Yoneyama, Hiroyuki Iijima; Factors associated with retreatment after photodynamic therapy combined with intravitreal ranibizumab for polypoidal choroidal vasculopathy. Invest. Ophthalmol. Vis. Sci. 2016;57(12):3332.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To investigate the retreatment incidence and its risk factors within 60 months after photodynamic therapy (PDT) combined with intravitreal ranibizumab (IVR) for treatment-naïve polypoidal choroidal vasculopathy (PCV).

Methods : We retrospectively reviewed the medical records of 61 eyes from 60 patients with PCV, who were followed-up for at least 12 months after the combination therapy. Retreatment including IVR or the combination therapy was conducted if residual or recurrence exudative changes were present. We investigated whether baseline clinical and genetic factors including ARMS2 A69S and CFH I62V, were associated with retreatment after the initial treatment.

Results : During follow-up period(mean:44±13 months, median 48 months),46 eyes(75.4%) received the retreatment. Survival analysis revealed that survival proportion was 59%, 41%, 31%, 24%, and 20% at 12-, 24-, 36-, 48- and 60-month visit, respectively. Median and mean retreatment free period was 15.0(95% confidence interval (CI):7.4-22.7) and 24.9(95% CI: 19.3-30.6) months, respectively. Mean best-corrected visual acuity (BCVA) significantly improved throughout follow-up periods except at 48-month visit. Cox regression analysis revealed that older age (P=0.011, hazard ratio 1.05 confidence interaval1.01-1.10) and male (P=0.018, hazard ratio 2.47 confidence interval 1.10-5.61) was associated with retreatment.

Conclusions : Visual outcomes 5 years after PDT combined with IVR were relatively favorable. Retreatment was required for about 80% eyes within 60 months after the combined therapy for PCV. Retreatment was associated with older age and male.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×